US · PULM
Pulmatrix, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Lexington, MA 02421
- Website
- pulmatrix.com
Price · as of 2025-12-31
$1.29
Market cap 10.92M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $192.12 | +14,793.02% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $560.00 | $5,975.31 | $0.00 | $0.00 | |
| 2016 | $670.00 | $268.00 | $0.00 | $0.00 | $7,873.68 |
| 2017 | $294.00 | $167.85 | $0.00 | $0.00 | $9,147.41 |
| 2018 | $35.40 | $14.30 | $0.00 | $0.00 | $4,375.75 |
| 2019 | $33.40 | $2,218.86 | $7,805.30 | $0.00 | $0.00 |
| 2020 | $30.20 | $4,346.95 | $62,415.64 | $0.00 | $0.00 |
| 2021 | $6.36 | $15.63 | $11.23 | $0.00 | $416.74 |
| 2022 | $3.28 | $11.84 | $3.05 | $0.00 | $0.00 |
| 2023 | $1.91 | $37.40 | $0.13 | $0.00 | $0.00 |
| 2024 | $7.16 | $109.12 | $0.00 | $0.00 | $0.00 |
| 2025 | $1.89 | $192.12 |
AI valuation
Our deep-learning model estimates Pulmatrix, Inc.'s (PULM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $192.12
- Current price
- $1.29
- AI upside
- +14,793.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PULM | Pulmatrix, Inc. | $1.29 | 10.92M | +14,793% | — | — | — | -1.34 | 1.81 | — | -0.55 | — | 1.81 | 0.00% | — | — | -80.93% | 1213.38% | -73.31% | 0.00 | — | 12.55 | 12.43 | 0.79 | -4618.00% | -10000.00% | -5112.00% | -78.71% | -16.51 | 1275.35% | 0.00% | 0.00% | 0.00% | -0.54 | -0.52 | — | -92.69 |
| ADTX | Aditxt, Inc. | $0.46 | 9.84K | +128,310,097% | +775,435,055% | — | +4,369,268,359% | 0.00 | 0.02 | 1.28 | 30.55 | -0.01 | 0.02 | -367.95% | -20796.36% | -25708.85% | -276.39% | 7.12% | -89.79% | 0.78 | -3.78 | 0.09 | 35.64 | -0.23 | 3863.00% | -7923.00% | -984.00% | -9785.19% | -0.72 | 4.28% | 0.00% | 0.00% | 8689.62% | 29.64 | 49.27 | -6164.42 | -10.97 |
| ASBP | Aspire Biopharma Holdings… | $1.39 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CTXR | Citius Pharmaceuticals, I… | $0.74 | 8.27M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| DARE | Daré Bioscience, Inc. | $1.70 | 16.19M | +12,485% | -31% | — | +2,345% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| FBLG | FibroBiologics, Inc. Comm… | $0.33 | 13.77M | — | — | — | — | -1.01 | 3.05 | — | -0.92 | -4.28 | 3.05 | 0.00% | — | — | -419.44% | -1119.26% | -143.08% | 0.39 | -81.61 | 3.61 | 2.78 | 0.14 | 2353.00% | — | 3782.00% | -88.80% | -9.32 | -1119.73% | 0.00% | 0.00% | 0.00% | -0.98 | -0.98 | — | -9.77 |
| HOTH | Hoth Therapeutics, Inc. | $1.01 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| LGVN | Longeveron Inc. | $0.54 | 11.55M | +7,909% | +29% | — | — | -1.41 | 1.03 | 9.40 | -0.30 | — | 1.15 | 78.76% | -690.72% | -667.77% | -111.59% | -439.24% | -84.88% | 0.07 | — | 7.60 | 7.48 | 1.14 | -8953.00% | 23738.00% | -2302.00% | -66.09% | -5.37 | -395.06% | 38.47% | -54.20% | 104.64% | -0.28 | -0.32 | 1.96 | -3.57 |
| LPTX | Leap Therapeutics, Inc. | $0.62 | 25.83M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| PALI | Palisade Bio, Inc. | $1.77 | 263.74M | +38% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
- CEO
- Peter Ludlum
- Employees
- 2
- Beta
- 1.71
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.29) − 1 = — (DCF, example).